Arkolith/Insider Trading/URGN/Form 4

Degnan Chris

Chief Financial OfficerUroGen Pharma Ltd. (URGN) · full profile →Form 4 · filed Oct 9, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$37K
Net Open-Market Flow
-$37K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 8, 2025Option exercise(M)4K——4K
Oct 8, 2025Sell(S)2K$16.85$37K2K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 8, 2025Option exercise(M)4K—$09K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-25-030772) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML